SMT202000523T1 - 6-aril-4-(morfolin-4-il)-1h-piridin-2-one composti utili per il trattamento di cancro e diabete - Google Patents
6-aril-4-(morfolin-4-il)-1h-piridin-2-one composti utili per il trattamento di cancro e diabeteInfo
- Publication number
- SMT202000523T1 SMT202000523T1 SM20200523T SMT202000523T SMT202000523T1 SM T202000523 T1 SMT202000523 T1 SM T202000523T1 SM 20200523 T SM20200523 T SM 20200523T SM T202000523 T SMT202000523 T SM T202000523T SM T202000523 T1 SMT202000523 T1 SM T202000523T1
- Authority
- SM
- San Marino
- Prior art keywords
- morpholin
- pyridin
- diabetes
- cancer
- aryl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156530 | 2016-02-19 | ||
| EP17705878.1A EP3416945B1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-one compounds useful for the treatment of cancer and diabetes |
| PCT/EP2017/053612 WO2017140841A1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000523T1 true SMT202000523T1 (it) | 2020-11-10 |
Family
ID=55404645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200523T SMT202000523T1 (it) | 2016-02-19 | 2017-02-17 | 6-aril-4-(morfolin-4-il)-1h-piridin-2-one composti utili per il trattamento di cancro e diabete |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11077113B2 (it) |
| EP (1) | EP3416945B1 (it) |
| JP (3) | JP6997462B2 (it) |
| CN (3) | CN113754581A (it) |
| AU (3) | AU2017219846B2 (it) |
| CA (1) | CA3015045A1 (it) |
| CY (1) | CY1123285T1 (it) |
| DK (1) | DK3416945T3 (it) |
| ES (1) | ES2816376T3 (it) |
| HR (1) | HRP20201400T1 (it) |
| HU (1) | HUE050863T2 (it) |
| LT (1) | LT3416945T (it) |
| PL (1) | PL3416945T3 (it) |
| PT (1) | PT3416945T (it) |
| RS (1) | RS60898B1 (it) |
| RU (1) | RU2754664C2 (it) |
| SI (1) | SI3416945T1 (it) |
| SM (1) | SMT202000523T1 (it) |
| TW (1) | TWI721104B (it) |
| WO (1) | WO2017140841A1 (it) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3015045A1 (en) * | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| US11179399B2 (en) * | 2016-02-19 | 2021-11-23 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
| JP7199736B2 (ja) | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | モルホリニルピリドン化合物 |
| ES2929424T3 (es) * | 2017-08-23 | 2022-11-29 | Sprint Bioscience Ab | Compuestos de piridinamina-piridona y pirimidinamina-piridona |
| KR102730718B1 (ko) * | 2017-08-23 | 2024-11-14 | 스프린트 바이오사이언스 아베 | 피리딜피리돈 화합물 |
| JP7199738B2 (ja) | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
| WO2020008046A1 (en) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarker |
| US20220315528A1 (en) * | 2019-08-21 | 2022-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| JP2023553809A (ja) | 2020-11-25 | 2023-12-26 | デシフェラ・ファーマシューティカルズ,エルエルシー | ウイルス感染の治療に使用するためのvsp34阻害剤としてのピリジルピリドン誘導体 |
| WO2022115549A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2316831E (pt) * | 2002-11-21 | 2013-06-06 | Novartis Ag | 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| BRPI1015943A8 (pt) | 2009-07-02 | 2018-01-09 | Sanofi Sa | derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica. |
| EA201390917A1 (ru) * | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014145512A2 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| JP6074043B2 (ja) * | 2013-08-29 | 2017-02-01 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリール及びその使用 |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| BR112017004704A2 (pt) * | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
| CA3015045A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
-
2017
- 2017-02-17 CA CA3015045A patent/CA3015045A1/en active Pending
- 2017-02-17 LT LTEP17705878.1T patent/LT3416945T/lt unknown
- 2017-02-17 CN CN202111121825.5A patent/CN113754581A/zh active Pending
- 2017-02-17 US US15/999,530 patent/US11077113B2/en active Active
- 2017-02-17 TW TW106105179A patent/TWI721104B/zh not_active IP Right Cessation
- 2017-02-17 EP EP17705878.1A patent/EP3416945B1/en active Active
- 2017-02-17 HR HRP20201400TT patent/HRP20201400T1/hr unknown
- 2017-02-17 CN CN202111123598.XA patent/CN113845472A/zh active Pending
- 2017-02-17 WO PCT/EP2017/053612 patent/WO2017140841A1/en not_active Ceased
- 2017-02-17 HU HUE17705878A patent/HUE050863T2/hu unknown
- 2017-02-17 RU RU2018131775A patent/RU2754664C2/ru active
- 2017-02-17 ES ES17705878T patent/ES2816376T3/es active Active
- 2017-02-17 SM SM20200523T patent/SMT202000523T1/it unknown
- 2017-02-17 PL PL17705878T patent/PL3416945T3/pl unknown
- 2017-02-17 JP JP2018562701A patent/JP6997462B2/ja active Active
- 2017-02-17 CN CN201780013738.3A patent/CN108698996B/zh active Active
- 2017-02-17 RS RS20201057A patent/RS60898B1/sr unknown
- 2017-02-17 SI SI201730395T patent/SI3416945T1/sl unknown
- 2017-02-17 DK DK17705878.1T patent/DK3416945T3/da active
- 2017-02-17 AU AU2017219846A patent/AU2017219846B2/en active Active
- 2017-02-17 PT PT177058781T patent/PT3416945T/pt unknown
-
2020
- 2020-08-27 CY CY20201100804T patent/CY1123285T1/el unknown
-
2021
- 2021-06-29 US US17/362,763 patent/US11633403B2/en active Active
- 2021-08-12 AU AU2021215234A patent/AU2021215234B2/en not_active Ceased
- 2021-12-08 JP JP2021199161A patent/JP7389504B2/ja active Active
-
2023
- 2023-03-09 US US18/181,046 patent/US20240050439A1/en not_active Abandoned
- 2023-10-13 AU AU2023248170A patent/AU2023248170A1/en not_active Abandoned
- 2023-11-10 JP JP2023192216A patent/JP2024016225A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3416945T (lt) | 6-aril-4-(morfolin-4-il)-1h-piridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui | |
| PT3416957T (pt) | Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| EP3402516A4 (en) | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER | |
| EP3245193A4 (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
| ZA201807653B (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL263793A (en) | Compounds and preparations for the treatment of cancer | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| IL247293B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| EP3185860A4 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| HK40001851A (en) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-one compounds useful for the treatment of cancer and diabetes | |
| HK40001851B (en) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-one compounds useful for the treatment of cancer and diabetes | |
| EP3242681B8 (en) | Novel compounds for the treatment of cancer | |
| HK40001850B (en) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes | |
| HK40001850A (en) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes | |
| AU2016901862A0 (en) | Treatment of diabetes |